Methods	Allocation: random, no further details. Blindness: double, identical capsules. Duration: 22 weeks (last 12 weeks observed). Design: parallel. Location: multicentre.
Participants	Diagnosis: (DSM-IV) schizophrenia (n = 24) or schizoaffective disorder (n = 12). N = 36. Sex: 17 M, 19 F. Age: mean = 47.0 years. History: duration ill not reported, age at onset not reported. Setting: outpatient.
Interventions	Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 13.8 mg/day. N = 17. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 5.3 mg/day. N= 19
Outcomes	Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore. Adverse effects: EPS (SAS), weight gain. Unable to use: Leaving the study early: no data.
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Random, no further details.
Allocation concealment?	Unclear risk	No further details.
Blinding? subjective outcomes	Unclear risk	Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding
Blinding? objective outcomes	Low risk	Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Incomplete outcome data addressed? All outcomes	High risk	Data on leaving the study early were not available.
Free of selective reporting?	High risk	Standard deviations for the primary outcome were not available
Free of other bias?	High risk	Dose ranges were not indicated. The study was sponsored by the manufacturer of risperidone